The oncology market is experiencing rapid sales growth, driven by increasing volume and higher prices as new drugs come to market. By 2009 it is forecast to be the largest sales value therapy area, at $55bn. Death from cancer is a major social issue for all developed countries.
The oncology pipeline is the richest in number and potential value, by far with a high number of pharmaceutical & biotech companies focusing on oncology drugs. 50-55 new oncology products will be launched within the next five years with new players entering the market. About 30% of all launches by 2010 will be in Oncology.
Using our analysis of the full patient treatment history of all anticancer therapies, we can work with you to optimize portfolio management, identify valuable market opportunities and evaluate competitor behavior.
In an increasingly competitive market, IMS adds value by providing analytics and consulting for:
- Market and competitor assessment
- Brand shaping decisions
- Predicting impact on the market place
- Pricing & reimbursement decisions
- Health economic analysis
IMS expertise is based on a complete clinical understanding of the patients' journey through the diagnosis, treatment and outcome.
IMS Oncology delivers new value in a complex and dynamic market, to manage the launch and lifecycle of anti-cancer agents; to identify market opportunities and evaluate the potential of markets and their segments; to assess market size and potential by tumor and stage of disease; to highlight potential competitor and off-label use from drugs in clinical trials and to show treatment cascades for major tumors, highlighting prescribing opportunities.